New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 30, 2014
09:03 EDTMNKMallinckrodt to present new data for Xartemis XR, Pennsaid 2%
Mallinckrodt will present new data for two of its recently approved pain medications XARTEMIS XR Extended-Release Tablets and PENNSAID 2% during the 33rd Annual Scientific Meeting of the American Pain Society to be held April 30 - May 3, 2014 in Tampa, Florida. XARTEMIS XR is an oral medication indicated for the management of acute pain severe enough to require opioid treatment in patients for whom alternative treatment options are ineffective, not tolerated or would otherwise be inadequate. It is the first and only oxycodone HCI/acetaminophen combination for acute pain with immediate- and extended-release analgesia, providing fast-acting and long-lasting pain relief with 12-hour dosing for patients. PENNSAID 2% is a topical non-steroidal anti-inflammatory drug approved for the treatment of the pain of osteoarthritis of the knee(s). The data to be presented on XARTEMIS XR evaluates pharmacokinetics in different populations, as well as pooled safety data from Phase III trials. The first presentation of pivotal efficacy and safety results for PENNSAID 2% in the treatment of pain for osteoarthritis of the knee will also be presented, as well as an assessment of pharmacokinetics and tolerability compared with the 1.5% PENNSAID formulation.
News For MNK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 27, 2015
07:57 EDTMNKMallinckrodt announces positive outcomes with H.P. Acthar gel in proteinuria
Subscribe for More Information
March 26, 2015
07:30 EDTMNKDeutsche Bank to hold a conference
Pharma One-on-One Day is being held in Denver, Colorado on March 26.
March 23, 2015
13:23 EDTMNKLeerink pharma/generics analyst has analyst/industry conference call
Specialty Pharmaceuticals/Generics Analyst Gerberry, discusses the strengths and weaknesses of INOmax's current patent portfolio, the likelihood Praxair's recently filed inter-partes review challenge succeeds on an Analyst/Industry conference call to be held on March 26 at 2 pm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use